Add Formweb to your mobile device
Search results for:
teclistamab
teclistamab
Brand names: Tecvayli
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, SUBCUTANEOUS | cqyv 10 mg/mL; cqyv 90 mg/mL |
Last updated: Dec. 9, 2024
teclistamab
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, SUBCUTANEOUS | cqyv 10 mg/mL; cqyv 90 mg/mL |
Due to the risk of CRS and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), patients should be hospitalized for 48 hours after all doses within the step-up dosing schedule (step-up doses 1 and 2, as well as the first treatment dose).